Dianthus TherapeuticsDNTH
DNTH
About: Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
Employees: 78
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
78% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 23
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
11.82% more ownership
Funds ownership: 106.86% [Q3] → 118.68% (+11.82%) [Q4]
4% more funds holding
Funds holding: 91 [Q3] → 95 (+4) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 5 (+0) [Q4]
11% less capital invested
Capital invested by funds: $859M [Q3] → $766M (-$92.9M) [Q4]
31% less call options, than puts
Call options by funds: $9K | Put options by funds: $13K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$36
65%
upside
Avg. target
$53
144%
upside
High target
$84
284%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Wedbush Laura Chico 9% 1-year accuracy 4 / 47 met price target | 65%upside $36 | Outperform Reiterated | 12 Mar 2025 |
Guggenheim Yatin Suneja 15% 1-year accuracy 5 / 34 met price target | 284%upside $84 | Buy Reiterated | 12 Mar 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 21% 1-year accuracy 40 / 192 met price target | 83%upside $40 | Buy Reiterated | 12 Mar 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
2 weeks ago
Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock?
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Negative
Zacks Investment Research
1 month ago
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.71 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results
Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H'25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H'26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 $357.0 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the fourth quarter and full year ending December 31, 2024 and provided an update on recent business achievements.
Neutral
GlobeNewsWire
1 month ago
Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors
Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion
Neutral
GlobeNewsWire
1 month ago
Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the following investor conferences:
Neutral
GlobeNewsWire
2 months ago
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences
NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of February:
Neutral
GlobeNewsWire
3 months ago
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the 43rd Annual J.P. Morgan Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, January 15, 2025 at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco.
Negative
Zacks Investment Research
5 months ago
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $3.78 per share a year ago.
Neutral
GlobeNewsWire
5 months ago
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE'24
Neutral
GlobeNewsWire
5 months ago
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during November and December 2024:
Charts implemented using Lightweight Charts™